CVS Health vs Roche

Goldman recommends defensive stocks amid AI bull concerns

Goldman Sachs advises investors concerned about a potential slowdown in the AI trade to consider defensive stocks in health care and consumer staples. The bank notes that AI capital spending currently contributes about half of S&P 500 earnings growth, but expects this to diminish as spending growth slows. Rising energy prices and interest rates are clouding the economic outlook, with higher financing costs raising doubts about the durability of the AI infrastructure buildout. Goldman's screen highlights companies with high free cash flow yields and recent underperformance, such as Tyson Foods (11% FCF yield, down 17% over six months) and CVS Health (9% FCF yield, down 15% in three months). Despite these defensive recommendations, Goldman's base case still expects continued earnings growth, with a potential catch-up trade in consumer-facing stocks fueled by weaker energy prices and falling interest rates anticipated in 2027.

• Goldman Sachs recommends defensive stocks in health care and consumer staples amid AI trade concerns.
• AI capital spending contributes about half of S&P 500 earnings growth, but Goldman expects this to diminish.
• Rising energy prices and interest rates are clouding the economic outlook.

10-Q Financial Filing Analysis for CVS Health (2026-08-05)

CVS Health Corporation reported strong financial results for the second quarter of 2026, driven by top-line growth across all major operating segments. Total revenues increased 7.3% year-over-year to $106.10 billion, up from $98.92 billion in Q2 2025. Operating income saw a substantial 97.5% increase to $4.70 billion, compared to $2.38 billion in the prior-year period, primarily supported by core operational improvements and the absence of $833 million in legacy litigation charges incurred in Q2 2025. Net income attributable to CVS Health rose significantly to $2.98 billion ($2.31 diluted EPS) from $1.02 billion ($0.80 diluted EPS). Performance in the Health Care Benefits segment reflected improved medical loss dynamics, with the Medical Benefit Ratio (MBR) declining to 87.4% from 89.9% in Q2 2025, driven by improved underlying Government business performance and the absence of prior-year premium deficiency reserves. Growth was supported by the Health Services segment, where revenues climbed 11.5% to $51.80 billion, and Pharmacy & Consumer Wellness, which posted a 2.9% increase in pharmacy same-store sales aided by Rite Aid file acquisitions. In regulatory matters, CVS reached a proposed settlement with the FTC to resolve outstanding PBM and pharmacy inquiries.

• Q2 2026 consolidated total revenues reached $106.10 billion, an increase of 7.3% year-over-year, with operating income increasing 97.5% to $4.70 billion.
• Health Care Benefits Medical Benefit Ratio (MBR) improved by 250 bps year-over-year to 87.4%, while total medical membership stood at 26.02 million as of June 30, 2026.
• Operating cash flow for the first six months of 2026 increased 64.2% year-over-year to $10.59 billion, supporting $3.29 billion in long-term debt repayments.

Pixability Appoints Norm de Greve, Former General Motors CMO and Chairman of the MMA, to its Advisory Board

Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, has joined the advisory board of Pixability, a leading AI-driven technology company that helps brands maximize YouTube advertising. In an interview with AdExchanger, de Greve highlights common mistakes brands make with YouTube marketing, emphasizing the need for an integrated strategy across paid, owned, and creator channels, which most brands lack. He also notes YouTube's growing importance as a top source for AI search and advocates for a holistic approach to content and creator management. De Greve critiques current AI use in marketing, urging brands to redesign workflows around AI rather than optimize old processes. Pixability's AI-driven approach aims to help marketers analyze organic content, amplify successful strategies, and allocate budgets more effectively across YouTube's ecosystem.

• Norm de Greve, former CMO of General Motors and CVS Health and Chairman of the MMA, joined Pixability's advisory board.
• Pixability is a YouTube-focused AI company that helps brands maximize paid and owned media and leverage creators.
• De Greve advises brands to integrate paid, owned, and creator YouTube strategies.

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.